GCTK (GlucoTrack, Inc.) Utang jangka cendhak marang modal

GlucoTrack, Inc. (GCTK) minimizes risks in endocrinology by developing wearable gadgets for blood sugar monitoring without skin penetration. This price chart reflects a market trend for the asset showing a net debt-to-equity ratio of 0.00. While the company plans to generate revenue through the implementation of non-invasive diabetes monitoring, the business currently operates on previous investments as the clinical testing stage is not yet profitable.

High expenditures by GlucoTrack, Inc. (GCTK) on clinical trials for non-invasive glucose monitoring systems are draining liquidity; consequently, the short-term debt-to-equity chart reflects a financing structure dependent on liabilities maturing within one year relative to equity, where any increase in this indicator signals a critical risk of a cash crunch and rising borrowing costs.